Advertisement

Topics

As Mystic unveiling nears, AZ keeps cancer options open with Chi-Med

08:31 EDT 29 Jun 2017 | pharmaphorum

AstraZeneca is just days away from unveiling data from its MYSTIC trial, a new lung cancer immunotherapy combination which carries huge expectations for the company. The MYSTIC trial combines the company’s Imfinzi (PD-L1 drug durvalumab, already...

Original Article: As Mystic unveiling nears, AZ keeps cancer options open with Chi-Med

NEXT ARTICLE

More From BioPortfolio on "As Mystic unveiling nears, AZ keeps cancer options open with Chi-Med"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...